Abstract
Metastasis of tumor cells from primary tumor and growth at secondary sites are the major cause of mortality in cancer patients. This event may occur years and even decades after successful removal of the primary tumor and adjuvant therapy. Relapse and metastasis are universally existed in various malignancies. This phenomenon is attributed to a small amount of residual tumor cells remained in host for years, which is called as dormancy. Tumor dormancy is characterized by the balanced cell proliferation and cell death, immune evasion from host, non-angiogenic feature, insufficiency of metastatic capacity, cell cycle arrest as well as resistant to conventional chemotherapy. The molecular expressing profile suggested that dormancy is a state of quiescent cancer stem-like cells (CSCs), which are more resistant to chemotherapy and targeted therapy. Hitherto, the progression on tumor dormancy is relatively slow because there are no proper experimental models and biomarkers for identifying the dormant cells. It is no doubt that clarifying the regulatory mechanism of enter or exit of dormancy will help scientists to develop targeted strategy for eliminating dormant tumor cells, and then hinder the distant relapse and metastasis for various malignancies. This review focuses on tumor dormancy, the association of tumor dormancy with CSCs and strengthens the angiogenic switch for enter or exit of dormancy. It enlightens researchers to explore and develop more specific targeted drugs for clearance of the relapse danger.
Keywords: Tumor dormancy, Distant relapse, Metastasis, Chemoresistance, Refractory
Anti-Cancer Agents in Medicinal Chemistry
Title:Cell Dormancy and Tumor Refractory
Volume: 13 Issue: 2
Author(s): Yingyan Yu and Zhenggang Zhu
Affiliation:
Keywords: Tumor dormancy, Distant relapse, Metastasis, Chemoresistance, Refractory
Abstract: Metastasis of tumor cells from primary tumor and growth at secondary sites are the major cause of mortality in cancer patients. This event may occur years and even decades after successful removal of the primary tumor and adjuvant therapy. Relapse and metastasis are universally existed in various malignancies. This phenomenon is attributed to a small amount of residual tumor cells remained in host for years, which is called as dormancy. Tumor dormancy is characterized by the balanced cell proliferation and cell death, immune evasion from host, non-angiogenic feature, insufficiency of metastatic capacity, cell cycle arrest as well as resistant to conventional chemotherapy. The molecular expressing profile suggested that dormancy is a state of quiescent cancer stem-like cells (CSCs), which are more resistant to chemotherapy and targeted therapy. Hitherto, the progression on tumor dormancy is relatively slow because there are no proper experimental models and biomarkers for identifying the dormant cells. It is no doubt that clarifying the regulatory mechanism of enter or exit of dormancy will help scientists to develop targeted strategy for eliminating dormant tumor cells, and then hinder the distant relapse and metastasis for various malignancies. This review focuses on tumor dormancy, the association of tumor dormancy with CSCs and strengthens the angiogenic switch for enter or exit of dormancy. It enlightens researchers to explore and develop more specific targeted drugs for clearance of the relapse danger.
Export Options
About this article
Cite this article as:
Yu Yingyan and Zhu Zhenggang, Cell Dormancy and Tumor Refractory, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020003
DOI https://dx.doi.org/10.2174/1871520611313020003 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member:
Current Medicinal Chemistry Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Innovative Treatment Approach for Cancer-Related Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery Tumor Angiogenesis: A Potential Target In Cancer Control by Phytochemicals
Current Cancer Drug Targets Elasticity Imaging via MRI: Basics, Overcoming the Waveguide Limit, and Clinical Liver Results
Current Medical Imaging Synergistic Effects of Linderanolide B Combined with Arbutin, PTU or Kojic Acid on Tyrosinase Inhibition
Current Pharmaceutical Biotechnology GCPII Imaging and Cancer
Current Medicinal Chemistry Cartilage Oligomeric Matrix Protein: Matricellular and Matricrine Signaling in Cardiovascular Homeostasis and Disease
Current Vascular Pharmacology Ectodomain Shedding and Regulated Intracellular Proteolysis in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Advancement of Traditional Chinese Medicine in Regulation of Intestinal Flora: Mechanism-based Role in Disease Management
Recent Patents on Anti-Cancer Drug Discovery Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets Synthesis and Biological Evaluation of Structurally Diverse Benzimidazole Scaffolds as Potential Chemotherapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry